Skip to main content
. 2021 Mar 30;10(4):759. doi: 10.3390/cells10040759

Figure 4.

Figure 4

SRPIN340 protected HeLa and T24 cells from the cytotoxic effects of 5-FU and cisplatin. HeLa cells (left panel) were treated with SRPIN340 (5–80 µM) for 48 h, 5-FU (5–50 μg/mL) for 48 h, 5-FU (20 μg/mL) plus SRPIN340 for 48 h, cisplatin (5–50 µM) for 24 h, or cisplatin (20 µM) plus SRPIN340 for 24 h. T24 cells (right panel) were treated with SRPIN340 (5–80 µM) for 48 h, 5-FU (2.5–50 μg/mL) for 48 h, 5-FU (5 μg/mL) plus SRPIN340 for 48 h, cisplatin (1–30 µM) for 48 h, or cisplatin (10 µM) plus SRPIN340 for 48 h. The number of viable cells was measured using an MTT assay. Viability is expressed as a percentage of the viability of untreated cells, which was set to 100 percent. The density and morphology of control and treated cells were also observed using an inverted phase-contrast microscope at 10× magnification. Images were captured at the same time points as the respective MTT assays.